Outcome Sciences, Inc. (OUTCOME) announced that the Agency for Healthcare Research and Quality (AHRQ) has awarded Outcome a task order to design and develop a new Registry of Patient Registries (RoPR) database.
Patient registries are increasingly being used to support a wide range of clinical studies. While clinical trials must be registered in ClinicalTrials.gov, there is no such mandate for observational studies. The goal of the RoPR database is to ensure registries are used in the most efficient manner and to encourage collaboration between patients and consumers, health care providers, researchers, research funding organizations, public health organizations, private health plans, employers, public insurance programs, journal editors, and pharmaceutical and device manufacturers. This project is being funded by the American Recovery and Reinvestment Act (ARRA), which is an economic stimulus package that was enacted by the 111th United States Congress in February 2009.
The main objectives of the RoPR project are to:
—Provide a searchable central listing of patient registries in the United States to enable interested parties to identify registries in a particular area;
—Encourage and facilitate the use of common data elements and definitions in similar conditions -- to improve opportunities for sharing, comparing
and linkage -- through the listing and searching of such elements;
—Provide a central repository of searchable summary results, including results for registries that have not published their findings in peer-reviewed literature;
—Offer researchers a search tool to locate existing data, from either ongoing studies or closed studies, to request for use in new studies;
and
—Serve as a recruitment tool for researchers and patients interested in participating in patient registries.
"A central repository for registries speaks to the evolution of these observational studies and their recognized importance in providing critical information about various disease states and medicines," said Dr. Richard Gliklich, MD, President and CEO of Outcome. "Outcome is honored to have been chosen by AHRQ to create the RoPR database, which we are confident will promote collaboration, reduce redundancy and improve transparency related to registries among various healthcare stakeholders."
The AHRQ task order also includes the development of the third edition of the guide, "Registries for Evaluating Patient Outcomes: A User's Guide," a Federal publication that provides information on designing, implementing, and evaluating patient registries. The guide addresses the strengths and limitations of patient registries, in addition to explaining how to design a registry, analyze and interpret registry data and evaluate the strength of a registry and its findings. Outcome led the development of the first and second editions of the patient registries guide. The third edition will provide more timely information regarding new methodological, legal, and operational challenges and advances. The updated guide will cover at least 11 new topics, and will be led by Dr. Gliklich and Dr. Nancy Dreyer, Chief of Scientific Affairs and Senior Vice President for Outcome. It is scheduled for release in 2013.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.